Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
basic toxicokinetics in vitro / ex vivo
Type of information:
read-across based on grouping of substances (category approach)
Adequacy of study:
key study
Justification for type of information:
A toxicokinetic assessment was performed based on data available for dilithium tetraborate. Based on the physical/chemical properties of dilithium tetraborate, absorption factors for this substance are derived to be 100% (oral), 100% (inhalation of aqueous aerosols) and 0.5% (dermal absorption from aqueous solutions) for risk assessment purposes. The bioaccumulation potential is expected to be low.

As the UVCB-Reaction products of boric acid and lithium hydroxidehas similar physicochemical properties ie. low vapour pressure and soluble in water then it is expected that the toxicokinetics assessment would be similar if not identical for the UVCB-Reaction products of boric acid and lithium hydroxide especially since all absorption factors derived were based on evidence for boric compounds such as boric acid. Both the inorganic borates, lithium tetrahydroxyborate and dilithium tetraborate, will be converted to boric acid at physiological pH in the aqueous layer on the surfaces of the mucosa. Boric acid is known to be readily taken up from the gastrointestinal tract in rats and humans, as demonstrated by experimental evidence in both human and animal studies, where more than 90% of the administered dose of borate was excreted as boric acid.

Sufficient evidence therefore exists to propose the same absorption factors for the toxicokinetics assessment. Read-across to dilithium tetraborate is proposed.

Data source

Materials and methods

Test material

Constituent 1
Chemical structure
Reference substance name:
Dilithium tetraborate
EC Number:
234-514-3
EC Name:
Dilithium tetraborate
Cas Number:
12007-60-2
Molecular formula:
B4Li2O7
IUPAC Name:
dilithium tetraborate
Test material form:
solid: bulk

Results and discussion

Applicant's summary and conclusion

Conclusions:
A toxicokinetics assessment was performed using the available data for diltihium tetraborate. The UVCB-Reaction products of boric acid and lithium hydroxide is sufficiently similar in terms of physicochemical properties and behaviour upon absorption that the same absorption factors can be used.
Executive summary:

A toxicokinetic assessment was performed based on the available data of dilithium tetraborate. Based on the physical/chemical properties of dilithium tetraborate, absorption factors for this substance are derived to be 100% (oral), 100% (inhalation of aqueous aerosols) and 0.5 % (dermal absorption from aqueous solutions) for risk assessment purposes. The bioaccumulation potential is expected to be low.


 


As the UVCB-Reaction products of boric acid and lithium hydroxide has similar physicochemical properties ie. low vapour pressure and soluble in water then it is expected that the toxicokinetics assessment would be similar if not identical for Reaction products of boric acid and lithium hydroxide.


especially since all absorption factors derived were based on evidence for boric compounds such as boric acid.  Both the inorganic borates, the UVCB-Reaction products of boric acid and lithium hydroxide and dilithium tetraborate, will be converted to boric acid at physiological pH in the aqueous layer on the surfaces of the mucosa. Boric acid is known to be readily taken up from the gastrointestinal tract in rats and humans, as demonstrated by experimental evidence in both human and animal studies, where more than 90% of the administered dose of borate was excreted as boric acid.  


Sufficient evidence therefore exists to propose the same absorption factors for the UVCB-Reaction products of boric acid and lithium hydroxide of 100% (oral), 100% (inhalation of aqueous aerosols) and 0.5 % (dermal absorption from aqueous solutions) for risk assessment purposes.